View in EDS

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.

Saved in:
Bibliographic Details
Title: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Authors: Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jegede OA; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Grilley-Olson JE; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Lauring JD; Johns Hopkins School of Medicine, Baltimore, MD., Mitchell EP; Thomas Jefferson University, Philadelphia, PA., Zwiebel JA; National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; National Cancer Institute, Bethesda, MD., Rubinstein LV; National Cancer Institute, Bethesda, MD., Patton D; National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Kono SA; Colorado Permanente Medical Group, Lone Tree, CO., Ford JM; Stanford University, Stanford, CA., Garcia AA; Louisiana State University Health Science Center, New Orleans, LA., Sui XD; Providence Regional Cancer System, Lacey, WA., Siegel RD; Bon Secours St Francis Hospital, Greenville, SC., Slomovitz BM; University of Miami, Miami, FL., Conley BA; National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA.
Source: JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100424.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35138919
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Krop+IE%22">Krop IE</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Jegede+OA%22">Jegede OA</searchLink>; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Grilley-Olson+JE%22">Grilley-Olson JE</searchLink>; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Lauring+JD%22">Lauring JD</searchLink>; Johns Hopkins School of Medicine, Baltimore, MD.<br /><searchLink fieldCode="AU" term="%22Mitchell+EP%22">Mitchell EP</searchLink>; Thomas Jefferson University, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Zwiebel+JA%22">Zwiebel JA</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gray+RJ%22">Gray RJ</searchLink>; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+V%22">Wang V</searchLink>; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Patton+D%22">Patton D</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Kono+SA%22">Kono SA</searchLink>; Colorado Permanente Medical Group, Lone Tree, CO.<br /><searchLink fieldCode="AU" term="%22Ford+JM%22">Ford JM</searchLink>; Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Garcia+AA%22">Garcia AA</searchLink>; Louisiana State University Health Science Center, New Orleans, LA.<br /><searchLink fieldCode="AU" term="%22Sui+XD%22">Sui XD</searchLink>; Providence Regional Cancer System, Lacey, WA.<br /><searchLink fieldCode="AU" term="%22Siegel+RD%22">Siegel RD</searchLink>; Bon Secours St Francis Hospital, Greenville, SC.<br /><searchLink fieldCode="AU" term="%22Slomovitz+BM%22">Slomovitz BM</searchLink>; University of Miami, Miami, FL.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; University of Texas Southwestern Medical Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100424.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35138919
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/PO.21.00424
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2100424
    Titles:
      – TitleFull: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Krop IE
      – PersonEntity:
          Name:
            NameFull: Jegede OA
      – PersonEntity:
          Name:
            NameFull: Grilley-Olson JE
      – PersonEntity:
          Name:
            NameFull: Lauring JD
      – PersonEntity:
          Name:
            NameFull: Mitchell EP
      – PersonEntity:
          Name:
            NameFull: Zwiebel JA
      – PersonEntity:
          Name:
            NameFull: Gray RJ
      – PersonEntity:
          Name:
            NameFull: Wang V
      – PersonEntity:
          Name:
            NameFull: McShane LM
      – PersonEntity:
          Name:
            NameFull: Rubinstein LV
      – PersonEntity:
          Name:
            NameFull: Patton D
      – PersonEntity:
          Name:
            NameFull: Williams PM
      – PersonEntity:
          Name:
            NameFull: Hamilton SR
      – PersonEntity:
          Name:
            NameFull: Kono SA
      – PersonEntity:
          Name:
            NameFull: Ford JM
      – PersonEntity:
          Name:
            NameFull: Garcia AA
      – PersonEntity:
          Name:
            NameFull: Sui XD
      – PersonEntity:
          Name:
            NameFull: Siegel RD
      – PersonEntity:
          Name:
            NameFull: Slomovitz BM
      – PersonEntity:
          Name:
            NameFull: Conley BA
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Harris LN
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Chen AP
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2022 Feb
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2473-4284
          Numbering:
            – Type: volume
              Value: 6
          Titles:
            – TitleFull: JCO precision oncology
              Type: main
ResultId 1